Omeros Corporation announced on April 8, 2025, that its proprietary Targeted Complement Activating Therapy (T-CAT) platform would be publicly presented for the first time at the European Congress on Infectious Diseases 2025 on April 14. The T-CAT platform develops novel pathogen-targeting recombinant antibodies designed for broad applicability against multidrug-resistant organisms (MDROs).
The mechanism of action for T-CAT recombinant monoclonal antibodies is unique, as they are engineered to contain an active complement-cleaving enzyme to trigger direct activation of complement on the microbial cell surface. This leads to microbial destruction and clearance, bypassing the limitations of conventional antibodies that rely on the classical pathway.
Preclinical studies in well-established animal models demonstrated the effectiveness of T-CAT recombinant antibodies in treating life-threatening infections caused by Gram-negative and Gram-positive bacterial pathogens. These studies showed significant reduction of bacteria from blood and lung tissues, as well as increased survival, without promoting drug resistance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.